Tevogen Bio Holdings Inc. Warrant

Tevogen Bio was recognized by NJBIZ for its innovative ExacTcell™ platform and AI technology, with projected near-term commercial potential of $1 billion in first-year revenue and a five-year forecast of $18-22 billion.

The global AI in healthcare market is projected to reach nearly $700 billion by 2034, growing at 38.5% annually. Companies are developing advanced AI diagnostic technologies targeting areas like diabetic retinopathy, cardiac screening, and chronic disease management, with increasing FDA approvals and commercial potential.